{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:02:00Z","timestamp":1794488520331,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Struct Mol Biol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Reduced protein abundance is the most frequent mechanism by which rare missense variants cause disease. A promising therapeutic avenue for treating reduced abundance variants is pharmacological chaperones (PCs, also known as correctors or stabilizers), small molecules that bind to and stabilize target proteins. PCs have been approved as clinical treatments for specific variants, but protein energetics suggest their effects might be much more general. To comprehensively assess PC efficacy for variation in a given protein, it is necessary to first assign the molecular mechanism explaining all pathogenic variants, then measure the response to the PC. Here we establish such a framework for the vasopressin 2 receptor (V2R), a G-protein-coupled receptor in which loss-of-function variants cause nephrogenic diabetes insipidus (NDI). Our data show that more than half of NDI variants are poorly expressed, highlighting loss of stability as the major pathogenic mechanism. Treatment with a PC rescues the expression of 87% of destabilized variants. The non-rescued variants identify the drug\u2019s predicted binding site. Our results provide proof-of-principle that small molecule binding can rescue destabilizing variants throughout a protein\u2019s structure. The application of this principle to other proteins should allow the development of effective therapies for many different rare diseases.<\/jats:p>","DOI":"10.1038\/s41594-025-01659-6","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T09:02:11Z","timestamp":1758531731000},"page":"2429-2440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A small molecule stabilizer rescues the surface expression of nearly all missense variants in a GPCR"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-4832","authenticated-orcid":false,"given":"Taylor L.","family":"Mighell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-1124","authenticated-orcid":false,"given":"Ben","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"1659_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S2213-8587(23)00042-6","volume":"11","author":"TLD Endocrinology","year":"2023","unstructured":"Endocrinology, T. L. D. &. Rare diseases: individually rare, collectively common. Lancet Diabetes Endocrinol. 11, 139 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1659_CR2","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049510","volume":"15","author":"BJ Livesey","year":"2022","unstructured":"Livesey, B. J. & Marsh, J. A. Interpreting protein variant effects with computational predictors and deep mutational scanning. Dis. Model. Mech. 15, dmm049510 (2022).","journal-title":"Dis. Model. Mech."},{"key":"1659_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013423 (2015).","journal-title":"Genet. Med."},{"key":"1659_CR4","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ajhg.2022.10.013","volume":"109","author":"V Pejaver","year":"2022","unstructured":"Pejaver, V. et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3\/BP4 criteria. Am. J. Hum. Genet. 109, 2163\u20132177 (2022).","journal-title":"Am. J. Hum. Genet."},{"key":"1659_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41586-024-08370-4","volume":"637","author":"A Beltran","year":"2025","unstructured":"Beltran, A., Jiang, X., Shen, Y. & Lehner, B. Site-saturation mutagenesis of 500 human protein domains. Nature 637, 885\u2013894 (2025).","journal-title":"Nature"},{"key":"1659_CR6","doi-asserted-by":"publisher","unstructured":"Cagiada, M., Jonsson, N. & Lindorff-Larsen, K. Decoding molecular mechanisms for loss of function variants in the human proteome. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.05.21.595203 (2024).","DOI":"10.1101\/2024.05.21.595203"},{"key":"1659_CR7","doi-asserted-by":"publisher","unstructured":"J\u00e4nes, J. et al. Predicted mechanistic impacts of human protein missense variants. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.05.29.596373 (2024).","DOI":"10.1101\/2024.05.29.596373"},{"key":"1659_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen, L. et al. Future therapies for cystic fibrosis. Nat. Commun. 14, 693 (2023).","journal-title":"Nat. Commun."},{"key":"1659_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/biom13081227","volume":"13","author":"I Keyzor","year":"2023","unstructured":"Keyzor, I. et al. Therapeutic role of pharmacological chaperones in lysosomal storage disorders: a review of the evidence and informed approach to reclassification. Biomolecules 13, 1227 (2023).","journal-title":"Biomolecules"},{"key":"1659_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9155","volume":"15","author":"H Song","year":"2023","unstructured":"Song, H. et al. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci. Transl. Med. 15, eabn9155 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1659_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger, A. C. & Fersht, A. R. The p53 Pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu. Rev. Biochem. 85, 375\u2013404 (2016).","journal-title":"Annu. Rev. Biochem."},{"key":"1659_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.phrs.2016.12.036","volume":"117","author":"P Beerepoot","year":"2017","unstructured":"Beerepoot, P., Nazari, R. & Salahpour, A. Pharmacological chaperone approaches for rescuing GPCR mutants: current state, challenges, and screening strategies. Pharmacol. Res. 117, 242\u2013251 (2017).","journal-title":"Pharmacol. Res."},{"key":"1659_CR14","doi-asserted-by":"publisher","first-page":"101359","DOI":"10.1016\/j.jbc.2021.101359","volume":"297","author":"AG McKee","year":"2021","unstructured":"McKee, A. G. et al. Systematic profiling of temperature- and retinal-sensitive rhodopsin variants by deep mutational scanning. J. Biol. Chem. 297, 101359 (2021).","journal-title":"J. Biol. Chem."},{"key":"1659_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1146\/annurev.biochem.052308.114844","volume":"78","author":"ET Powers","year":"2009","unstructured":"Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W. & Balch, W. E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959\u2013991 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"1659_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.sbi.2009.08.003","volume":"19","author":"N Tokuriki","year":"2009","unstructured":"Tokuriki, N. & Tawfik, D. S. Stability effects of mutations and protein evolvability. Curr. Opin. Struct. Biol. 19, 596\u2013604 (2009).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1659_CR17","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1021\/acs.biochem.6b00537","volume":"55","author":"BM Kroncke","year":"2016","unstructured":"Kroncke, B. M. et al. Documentation of an Imperative to Improve Methods for Predicting Membrane Protein Stability. Biochemistry 55, 5002\u20135009 (2016).","journal-title":"Biochemistry"},{"key":"1659_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-023-06328-6","volume":"620","author":"K Tsuboyama","year":"2023","unstructured":"Tsuboyama, K. et al. Mega-scale experimental analysis of protein folding stability in biology and design. Nature 620, 434\u2013444 (2023).","journal-title":"Nature"},{"key":"1659_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s42004-023-01019-9","volume":"6","author":"GA Ross","year":"2023","unstructured":"Ross, G. A. et al. The maximal and current accuracy of rigorous protein-ligand binding free energy calculations. Commun. Chem. 6, 222 (2023).","journal-title":"Commun. Chem."},{"key":"1659_CR20","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1021\/bi00489a001","volume":"29","author":"JA Wells","year":"1990","unstructured":"Wells, J. A. Additivity of mutational effects in proteins. Biochemistry 29, 8509\u20138517 (1990).","journal-title":"Biochemistry"},{"key":"1659_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41586-024-07966-0","volume":"634","author":"AJ Faure","year":"2024","unstructured":"Faure, A. J. et al. The genetic architecture of protein stability. Nature 634, 995\u20131003 (2024).","journal-title":"Nature"},{"key":"1659_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0008-6363(01)00337-6","volume":"51","author":"M Birnbaumer","year":"2001","unstructured":"Birnbaumer, M. The V2 vasopressin receptor mutations and fluid homeostasis. Cardiovasc. Res. 51, 409\u2013415 (2001).","journal-title":"Cardiovasc. Res."},{"key":"1659_CR23","doi-asserted-by":"crossref","unstructured":"Erd\u00e9lyi, L. S., Hunyady, L. & Balla, A. V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology. Front. Endocrinol. 14, 1173601 (2023).","DOI":"10.3389\/fendo.2023.1173601"},{"key":"1659_CR24","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/ki.1996.252","volume":"49","author":"DG Bichet","year":"1996","unstructured":"Bichet, D. G. Vasopressin receptors in health and disease. Kidney Int. 49, 1706\u20131711 (1996).","journal-title":"Kidney Int."},{"key":"1659_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrneph.2015.89","volume":"11","author":"D Bockenhauer","year":"2015","unstructured":"Bockenhauer, D. & Bichet, D. G. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat. Rev. Nephrol. 11, 576\u2013588 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"1659_CR26","first-page":"66","volume":"4","author":"SM Rosenthal","year":"2006","unstructured":"Rosenthal, S. M., Feldman, B. J., Vargas, G. A. & Gitelman, S. E. Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction. Pediatr. Endocrinol. Rev. 4, 66\u201370 (2006).","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"1659_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10157-012-0726-z","volume":"17","author":"S Sasaki","year":"2013","unstructured":"Sasaki, S., Chiga, M., Kikuchi, E., Rai, T. & Uchida, S. Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2. Clin. Exp. Nephrol. 17, 338\u2013344 (2013).","journal-title":"Clin. Exp. Nephrol."},{"key":"1659_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/jcp.21552","volume":"217","author":"E Spanakis","year":"2008","unstructured":"Spanakis, E., Milord, E. & Gragnoli, C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J. Cell. Physiol. 217, 605\u2013617 (2008).","journal-title":"J. Cell. Physiol."},{"key":"1659_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"1659_CR30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1681\/ASN.V1161044","volume":"11","author":"M-FC Arthus","year":"2000","unstructured":"Arthus, M.-F. C. et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 11, 1044 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1659_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1172\/JCI8688","volume":"105","author":"J-P Morello","year":"2000","unstructured":"Morello, J.-P. et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105, 887\u2013895 (2000).","journal-title":"J. Clin. Invest."},{"key":"1659_CR32","doi-asserted-by":"publisher","first-page":"e0181830","DOI":"10.1371\/journal.pone.0181830","volume":"12","author":"JA Janovick","year":"2017","unstructured":"Janovick, J. A., Spicer, T. P., Bannister, T. D., Scampavia, L. & Conn, P. M. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias. PLoS One 12, e0181830 (2017).","journal-title":"PLoS One"},{"key":"1659_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73089-x","volume":"10","author":"F Prosperi","year":"2020","unstructured":"Prosperi, F. et al. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. Sci. Rep. 10, 16383 (2020).","journal-title":"Sci. Rep."},{"key":"1659_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2265.2008.03513.x","volume":"71","author":"SA Ranadive","year":"2009","unstructured":"Ranadive, S. A. et al. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin. Endocrinol. 71, 388\u2013393 (2009).","journal-title":"Clin. Endocrinol."},{"key":"1659_CR35","doi-asserted-by":"publisher","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","volume":"292","author":"JH Robben","year":"2007","unstructured":"Robben, J. H., Sze, M., Knoers, N. V. A. M. & Deen, P. M. T. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am. J. Physiol. Ren. Physiol. 292, F253\u2013F260 (2007).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1659_CR36","doi-asserted-by":"publisher","first-page":"e0288158","DOI":"10.1371\/journal.pone.0288158","volume":"18","author":"TL Mighell","year":"2023","unstructured":"Mighell, T. L., Toledano, I. & Lehner, B. SUNi mutagenesis: scalable and uniform nicking for efficient generation of variant libraries. PLoS ONE 18, e0288158 (2023).","journal-title":"PLoS ONE"},{"key":"1659_CR37","doi-asserted-by":"publisher","first-page":"eaay7505","DOI":"10.1126\/sciadv.aay7505","volume":"6","author":"WD Penn","year":"2020","unstructured":"Penn, W. D. et al. Probing biophysical sequence constraints within the transmembrane domains of rhodopsin by deep mutational scanning. Sci. Adv. 6, eaay7505 (2020).","journal-title":"Sci. Adv."},{"key":"1659_CR38","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.4049\/jimmunol.1800343","volume":"200","author":"JD Heredia","year":"2018","unstructured":"Heredia, J. D. et al. Mapping interaction sites on human chemokine receptors by deep mutational scanning. J. Immunol. 200, 3825\u20133839 (2018).","journal-title":"J. Immunol."},{"key":"1659_CR39","first-page":"e1","volume":"48","author":"KA Matreyek","year":"2020","unstructured":"Matreyek, K. A., Stephany, J. J., Chiasson, M. A., Hasle, N. & Fowler, D. M. An improved platform for functional assessment of large protein libraries in mammalian cells. Nucleic Acids Res. 48, e1 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1659_CR40","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1021\/acs.jctc.9b01136","volume":"16","author":"A Heifetz","year":"2020","unstructured":"Heifetz, A. et al. Characterizing interhelical interactions of G-protein coupled receptors with the fragment molecular orbital method. J. Chem. Theory Comput. 16, 2814\u20132824 (2020).","journal-title":"J. Chem. Theory Comput."},{"key":"1659_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature11896","volume":"494","author":"AJ Venkatakrishnan","year":"2013","unstructured":"Venkatakrishnan, A. J. et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185\u2013194 (2013).","journal-title":"Nature"},{"key":"1659_CR42","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/nature06387","volume":"450","author":"T Hessa","year":"2007","unstructured":"Hessa, T. et al. Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature 450, 1026\u20131030 (2007).","journal-title":"Nature"},{"key":"1659_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/glycob\/9.7.731","volume":"9","author":"H Sadeghi","year":"1999","unstructured":"Sadeghi, H. & Birnbaumer, M. O-Glycosylation of the V2 vasopressin receptor. Glycobiology 9, 731\u2013737 (1999).","journal-title":"Glycobiology"},{"key":"1659_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1124\/mol.52.1.21","volume":"52","author":"HM Sadeghi","year":"1997","unstructured":"Sadeghi, H. M., Innamorati, G., Dagarag, M. & Birnbaumer, M. Palmitoylation of the V2 vasopressin receptor. Mol. Pharmacol. 52, 21\u201329 (1997).","journal-title":"Mol. Pharmacol."},{"key":"1659_CR45","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1659_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/humu.10212","volume":"21","author":"PD Stenson","year":"2003","unstructured":"Stenson, P. D. et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577\u2013581 (2003).","journal-title":"Hum. Mutat."},{"key":"1659_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65996-w","volume":"10","author":"V Vezzi","year":"2020","unstructured":"Vezzi, V. et al. Vasopressin receptor 2 mutations in the nephrogenic syndrome of inappropriate antidiuresis show different mechanisms of constitutive activation for G protein coupled receptors. Sci. Rep. 10, 9111 (2020).","journal-title":"Sci. Rep."},{"key":"1659_CR48","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41588-023-01465-0","volume":"55","author":"N Brandes","year":"2023","unstructured":"Brandes, N., Goldman, G., Wang, C. H., Ye, C. J. & Ntranos, V. Genome-wide prediction of disease variant effects with a deep protein language model. Nat. Genet. 55, 1512\u20131522 (2023).","journal-title":"Nat. Genet."},{"key":"1659_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41586-021-04043-8","volume":"599","author":"J Frazer","year":"2021","unstructured":"Frazer, J. et al. Disease variant prediction with deep generative models of evolutionary data. Nature 599, 91\u201395 (2021).","journal-title":"Nature"},{"key":"1659_CR50","doi-asserted-by":"publisher","first-page":"eadg7492","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).","journal-title":"Science"},{"key":"1659_CR51","doi-asserted-by":"publisher","first-page":"e82593","DOI":"10.7554\/eLife.82593","volume":"12","author":"LM Blaabjerg","year":"2023","unstructured":"Blaabjerg, L. M. et al. Rapid protein stability prediction using deep learning representations. eLife 12, e82593 (2023).","journal-title":"eLife"},{"key":"1659_CR52","doi-asserted-by":"publisher","first-page":"e2314853121","DOI":"10.1073\/pnas.2314853121","volume":"121","author":"H Dieckhaus","year":"2024","unstructured":"Dieckhaus, H., Brocidiacono, M., Randolph, N. Z. & Kuhlman, B. Transfer learning to leverage larger datasets for improved prediction of protein stability changes. Proc. Natl Acad. Sci. USA 121, e2314853121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1659_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/358761a0","volume":"358","author":"GM Denning","year":"1992","unstructured":"Denning, G. M. et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761\u2013764 (1992).","journal-title":"Nature"},{"key":"1659_CR54","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-genom-083118-014857","volume":"20","author":"J Domingo","year":"2019","unstructured":"Domingo, J., Baeza-Centurion, P. & Lehner, B. The causes and consequences of genetic interactions (epistasis). Annu. Rev. Genomics Hum. Genet. 20, 433\u2013460 (2019).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"1659_CR55","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.jbc.2022.102266","volume":"298","author":"FJ Roushar","year":"2022","unstructured":"Roushar, F. J. et al. Molecular basis for variations in the sensitivity of pathogenic rhodopsin variants to 9-cis-retinal. J. Biol. Chem. 298, 102266 (2022).","journal-title":"J. Biol. Chem."},{"key":"1659_CR56","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.chembiol.2023.05.001","volume":"30","author":"AG McKee","year":"2023","unstructured":"McKee, A. G. et al. General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants. Cell Chem. Biol. 30, 632\u2013642(2023).","journal-title":"Cell Chem. Biol."},{"key":"1659_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1681\/ASN.2005080854","volume":"17","author":"V Bernier","year":"2006","unstructured":"Bernier, V. et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. JASN 17, 232\u2013243 (2006).","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"1659_CR58","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrd2946","volume":"8","author":"JK Ghali","year":"2009","unstructured":"Ghali, J. K., Hamad, B., Yasothan, U. & Kirkpatrick, P. Tolvaptan. Nat. Rev. Drug Discov. 8, 611\u2013612 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1659_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DHPS.S338050","volume":"14","author":"R Raina","year":"2022","unstructured":"Raina, R. et al. Clinical utility and tolerability of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Drug Healthc. Patient Saf. 14, 147\u2013159 (2022).","journal-title":"Drug Healthc. Patient Saf."},{"key":"1659_CR60","doi-asserted-by":"publisher","first-page":"811836","DOI":"10.3389\/fphar.2022.811836","volume":"13","author":"L Szalai","year":"2022","unstructured":"Szalai, L. et al. Functional rescue of a nephrogenic diabetes insipidus causing mutation in the V2 vasopressin receptor by specific antagonist and agonist pharmacochaperones. Front. Pharmacol. 13, 811836 (2022).","journal-title":"Front. Pharmacol."},{"key":"1659_CR61","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1074\/jbc.M111.268797","volume":"287","author":"K Takahashi","year":"2012","unstructured":"Takahashi, K. et al. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists. J. Biol. Chem. 287, 2099\u20132106 (2012).","journal-title":"J. Biol. Chem."},{"key":"1659_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2014.11.001","volume":"36","author":"V Isberg","year":"2015","unstructured":"Isberg, V. et al. Generic GPCR residue numbers - aligning topology maps while minding the gaps. Trends Pharmacol. Sci. 36, 22\u201331 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"1659_CR63","first-page":"3784","volume":"23","author":"H-L Liu","year":"2024","unstructured":"Liu, H.-L. et al. Structural basis of tolvaptan binding to the vasopressin V2 receptor. Acta Pharmacol. Sin. 23, 3784\u20133799 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"1659_CR64","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1124\/mol.106.029470","volume":"71","author":"GE Rovati","year":"2007","unstructured":"Rovati, G. E., Capra, V. & Neubig, R. R. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol. Pharmacol. 71, 959\u2013964 (2007).","journal-title":"Mol. Pharmacol."},{"key":"1659_CR65","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ajhg.2020.04.014","volume":"106","author":"TL Mighell","year":"2020","unstructured":"Mighell, T. L., Thacker, S., Fombonne, E., Eng, C. & O\u2019Roak, B. J. An integrated deep-mutational-scanning approach provides clinical insights on PTEN genotype\u2013phenotype relationships. Am. J. Hum. Genet. 106, 818\u2013829 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"1659_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45829-4","volume":"15","author":"L Clausen","year":"2024","unstructured":"Clausen, L. et al. A mutational atlas for Parkin proteostasis. Nat. Commun. 15, 1541 (2024).","journal-title":"Nat. Commun."},{"key":"1659_CR67","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.ajhg.2021.07.001","volume":"108","author":"CJ Amorosi","year":"2021","unstructured":"Amorosi, C. J. et al. Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. Am. J. Hum. Genet. 108, 1735\u20131751 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"1659_CR68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41586-023-06954-0","volume":"626","author":"C Weng","year":"2024","unstructured":"Weng, C., Faure, A. J., Escobedo, A. & Lehner, B. The energetic and allosteric landscape for KRAS inhibition. Nature 626, 643\u2013652 (2024).","journal-title":"Nature"},{"key":"1659_CR69","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.bpj.2022.12.031","volume":"122","author":"JKS Tiemann","year":"2023","unstructured":"Tiemann, J. K. S., Zschach, H., Lindorff-Larsen, K. & Stein, A. Interpreting the molecular mechanisms of disease variants in human transmembrane proteins. Biophys. J. 122, 2176\u20132191 (2023).","journal-title":"Biophys. J."},{"key":"1659_CR70","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.molcel.2024.04.008","volume":"84","author":"SW Yee","year":"2024","unstructured":"Yee, S. W. et al. The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics. Mol. Cell 84, 1932\u20131947(2024).","journal-title":"Mol. Cell"},{"key":"1659_CR71","doi-asserted-by":"publisher","first-page":"e76903","DOI":"10.7554\/eLife.76903","volume":"11","author":"W Coyote-Maestas","year":"2022","unstructured":"Coyote-Maestas, W., Nedrud, D., He, Y. & Schmidt, D. Determinants of trafficking, conduction, and disease within a K+ channel revealed through multiparametric deep mutational scanning. eLife 11, e76903 (2022).","journal-title":"eLife"},{"key":"1659_CR72","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.cell.2024.11.036","volume":"188","author":"MK Howard","year":"2025","unstructured":"Howard, M. K. et al. Molecular basis of proton-sensing by G protein-coupled receptors. Cell 188, 671\u2013687 (2025).","journal-title":"Cell"},{"key":"1659_CR73","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E21-11-0578","volume":"33","author":"EF McDonald","year":"2022","unstructured":"McDonald, E. F., Sabusap, C. M. P., Kim, M. & Plate, L. Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants. Mol. Biol. Cell 33, ar62 (2022).","journal-title":"Mol. Biol. Cell"},{"key":"1659_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45621-4","volume":"15","author":"D Ding","year":"2024","unstructured":"Ding, D. et al. Protein design using structure-based residue preferences. Nat. Commun. 15, 1639 (2024).","journal-title":"Nat. Commun."},{"key":"1659_CR75","doi-asserted-by":"publisher","first-page":"7953","DOI":"10.1038\/s41467-024-51895-5","volume":"15","author":"Y Park","year":"2024","unstructured":"Park, Y., Metzger, B. P. H. & Thornton, J. W. The simplicity of protein sequence-function relationships. Nat. Commun. 15, 7953 (2024).","journal-title":"Nat. Commun."},{"key":"1659_CR76","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41588-018-0122-z","volume":"50","author":"KA Matreyek","year":"2018","unstructured":"Matreyek, K. A. et al. Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat. Genet. 50, 874\u2013882 (2018).","journal-title":"Nat. Genet."},{"key":"1659_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41586-022-04586-4","volume":"604","author":"AJ Faure","year":"2022","unstructured":"Faure, A. J. et al. Mapping the energetic and allosteric landscapes of protein binding domains. Nature 604, 175\u2013183 (2022).","journal-title":"Nature"},{"key":"1659_CR78","doi-asserted-by":"publisher","first-page":"21030","DOI":"10.1073\/pnas.1315194110","volume":"110","author":"JA Janovick","year":"2013","unstructured":"Janovick, J. A. et al. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Proc. Natl Acad. Sci. USA 110, 21030\u201321035 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1659_CR79","doi-asserted-by":"crossref","unstructured":"Ren\u00e9, P., Lanfray, D., Richard, D. & Bouvier, M. Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity. JCI Insight 6, e132778 (2021).","DOI":"10.1172\/jci.insight.132778"},{"key":"1659_CR80","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.21105\/joss.01915","volume":"4","author":"KHD Crawford","year":"2019","unstructured":"Crawford, K. H. D. & Bloom, J. D. alignparse: a Python package for parsing complex features from high-throughput long-read sequencing. J. Open Source Softw. 4, 1915 (2019).","journal-title":"J. Open Source Softw."},{"key":"1659_CR81","doi-asserted-by":"publisher","first-page":"e2584","DOI":"10.7717\/peerj.2584","volume":"4","author":"T Rognes","year":"2016","unstructured":"Rognes, T., Flouri, T., Nichols, B., Quince, C. & Mah\u00e9, F. VSEARCH: a versatile open source tool for metagenomics. PeerJ 4, e2584 (2016).","journal-title":"PeerJ"},{"key":"1659_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10\u201312 (2011).","journal-title":"EMBnet. J."},{"key":"1659_CR83","doi-asserted-by":"crossref","unstructured":"Seabold, S. & Perktold, J. Statsmodels: econometric and statistical modeling with Python. Proc. 9th Python Science Conference 92\u201396 (SciPy, 2010).","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"1659_CR84","doi-asserted-by":"publisher","unstructured":"Lehner, B. & Mighell, T. A pharmacological chaperone stabilizer rescues the expression of the vast majority of pathogenic variants in a G protein-coupled receptor. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14216035 (2024).","DOI":"10.5281\/zenodo.14216035"}],"updated-by":[{"DOI":"10.1038\/s41594-025-01734-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000}}],"container-title":["Nature Structural &amp; Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41594-025-01659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-025-01659-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-025-01659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:02:23Z","timestamp":1765612943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41594-025-01659-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1038\/s41594-025-01659-6","relation":{},"ISSN":["1545-9993","1545-9985"],"issn-type":[{"value":"1545-9993","type":"print"},{"value":"1545-9985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41594-025-01734-y","URL":"https:\/\/doi.org\/10.1038\/s41594-025-01734-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L. is a founder and shareholder of ALLOX. T.L.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}